QYSCORE®

Advanced automated MRI analysis : delivering rapid, precise, and objective quantitative insights into CNS disorders

The **future** of neuroimaging is **here**

Eligible for reimbursement under a Category I CPT Code*
FDA Cleared and CE marked **

QYNAPSE

HEALTH SYSTEMS | PRIVATE CLINICS | CLINICAL TRIALS | RESEARCH INSTITUTIONS

QyScore® is a groundbreaking neuroimaging analysis **software** that supports the clinical assessment and monitoring of CNS diseases

Indications:

- Alzheimer's Disease & Other Dementias (including Fronto-Temporal Dementia, Lewy Body Dementia, Vascular Dementia)
- Multiple Sclerosis
- Parkinson's Disease & Other Movement Disorders

Volumetric Markers:

- Whole Brain
- Frontal, Temporal, Parietal and Occipital Cortical Lobes
- Hippocampus, Amygdala
- White Matter Hyperintensities

CE-marked FDA-cleared (510k)

- Lateral Ventricles***
- Caudate Nucleus, Putamen, Globus Pallidus and Thalamus***
- Cerebellum & Brainstem***
- T1 Hypointensities***

More than **200 other measures** for clinical trials & other research settings, including fMRI, diffusion MRI and PET analyses***

QyScore®'s results are generated in comparison to a **large normative database of 3000+ healthy subjects**

Robust,[1] accurate[2] **algorithms** with **strong reproducibility**[3], supported by 32 **scientific publications**

1) Tran et al. NeuroImage Clinical 2022. 2) Cavedo et al., European Radiology 2022 3) Morales-Pinzón A., Wallack M., Cavallari M., et al. (Poster ACTRIMS Forum 2022)

****Used in Clinical Trials*– not cleared or approved for clinical routine use

Seamless integration into Clinical workflows

Software delivered as a Service (SaaS) for global rollout



QYSCORE®



Interface and reports adapted to your needs

Standard MR sequence acquisition parameters

Scan the QR code to access to required acquisition parameters

Scientifically Proven Performance

Validated segmentation and measurements

- in comparison to gold-standard manual methods

Fast segmentation process saves time

- in comparison to manual and semi-automatic methods

Results published in **European Radiology Journal (2022), scan the QR code to read**
Cavedo E., et al. Eur Radiol 32, 2949–2961 (2022). https://doi.org/10.1007/s00330-021-08385-9

High reproducibility

- consistent **scan-rescan** results for Brain Volumetric and White Matter Hyperintensities across scanner and repeated timepoints





Morales-Pinzón A., Wallack M., Cavallari M., et al. (Poster ACTRIMS Forum 2022)

QYSCORE®

Scientifically Proven Performance

Proven superior performance versus open-source methods[1]

When compared with 6 widely-used open-source methods for the segmentation of WMH:

- QyScore® achieved a significantly higher Dice Similarity Coefficient (DSC: overlap of WMH segmentation compared with the gold-stand) versus other methods which showed lower gold-standard concordance using the Wilcoxon test (p-value < 0.001) - see below
- Validation based on gold-standard **consensus** reference (manual segmentation of 3 expert neuroradiologist on 30 subjects)

1 Results published in Neuroimage: Clinical Journal (2022)
scan the QR code to read Tran P., et al. Neuroimage Clin. 2022;33:102940.



Together is the only way forward towards a future of accurate diagnosis and treatment for CNS diseases.

QYNAPSE

www.qynapse.com

Scan the QR code to access this brochure in PDF format

QyScore® is a medical device software, FDA-cleared - class II and CE marked – class IIa. according to 2017/745 Regulation

*Category I CPT Code 76377 - "3D rendering with interpretation and reporting of computed tomography, magnetic resonance imaging,ultrasound, or other tomographic modality with image postprocessing under concurrent supervision; requiring image postprocessing on an independent workstation." This information is provided for general information only and does not constitute legal, coding, billing, or reimbursement advice. Coding and reimbursement decisions are made by payors and vary by jurisdiction and clinical context. No reimbursement is guaranteed..

Indications for Use in the U.S. (FDA): QyScore® is intended for automatic labeling, visualization and volumetric quantification of segmentable brain structures and lesions from a set of MR images. Volumetric data may be compared to reference percentile data. QyScore® is not intended for use in clinical scenarios that require evaluation of the number of the white matter hyperintensities
Indications for Use in Europe (CE): QyScore® is an advanced processing and visualization software for automatic labeling and volumetric quantification of segmented central nervous system structures for patients older than 18 years of age. The software is intended to be used by medical personnel or neuroimaging trained personnel to support diagnosis of central nervous system diseases.

Manufacturer
Qynapse - 2-10 rue d'Oradour-sur-Glane- 75015 PARIS – France - E-mail: contact@qynapse.com

Qynapse is ISO 13485 Certified, HIPAA Compliant, GDPR Compliant, and 21 CFR Part 11 Compliant

C-40-EN-01/2026